<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01147276</url>
  </required_header>
  <id_info>
    <org_study_id>Lund University Diabetes 002</org_study_id>
    <nct_id>NCT01147276</nct_id>
  </id_info>
  <brief_title>Vildagliptin and the Glucagon Response to Hypoglycemia in Type 1 Diabetes</brief_title>
  <official_title>Study of the Effect of Vildagliptin on Glucagon Counterregulation Response During Hypoglycemia in Patients With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lund University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lund University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study examines whether DPP-4 inhibition by vildagliptin affects the glucagon
      counterregulatory response to hypoglycemia in type 1 diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Vildagliptin (50 mg BID) or placebo is given as add-on to insulin treatment for four weeks in
      patients with type 1 diabetes. Then, a hypoglycemic clamp (2.5 mmol/l glucose) is undertaken
      with the determination of glucagon.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2010</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucagon response to hypoglycemia</measure>
    <time_frame>45 min</time_frame>
    <description>Change in glucagon from before hypoglycemic clamp until after 45 min</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Catecholamine response to hypoglycemic</measure>
    <time_frame>45 min</time_frame>
    <description>Change in catecholamines from before hypolycemic clamp to 45 min</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">28</enrollment>
  <condition>Diabetes</condition>
  <condition>Hypoglycemia</condition>
  <arm_group>
    <arm_group_label>Vildagliptin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vildagliptin (50 mg BID) given for four weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vildagliptin</intervention_name>
    <description>Vildagliptin (50 mg BID) in four weeks</description>
    <arm_group_label>Vildagliptin</arm_group_label>
    <other_name>Galvus</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Type 1 diabetes

          -  Age &gt;18 years

          -  HbA1c 6.5-8,5%

        Exclusion Criteria:

          -  Pregnancy

          -  Lactation

          -  Acute infection

          -  Liver disease

          -  Treatment with cortisol
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bo Ahr√©n, PhD MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Lund University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Clinical Sciences Lund, Lund University</name>
      <address>
        <city>Lund</city>
        <zip>221 84</zip>
        <country>Sweden</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 17, 2010</study_first_submitted>
  <study_first_submitted_qc>June 17, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 22, 2010</study_first_posted>
  <last_update_submitted>September 21, 2012</last_update_submitted>
  <last_update_submitted_qc>September 21, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 25, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lund University</investigator_affiliation>
    <investigator_full_name>Bo Ahren</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>DPP-4</keyword>
  <keyword>GLP-1</keyword>
  <keyword>Glucagon</keyword>
  <keyword>Catecholamines</keyword>
  <keyword>Counterregulation</keyword>
  <keyword>Type 1 diabetes</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Glucagon</mesh_term>
    <mesh_term>Glucagon-Like Peptide 1</mesh_term>
    <mesh_term>Vildagliptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

